PASADENA, Calif. --(BUSINESS WIRE)--Apr. 22, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 7, 2020 , at 4:30 p.m. EDT to discuss its financial results for the fiscal second quarter ended March 31, 2020 .
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 10, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to begin a Phase 1/2a clinical trial of ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 11, 2020 , the Compensation Committee of the Board of Directors approved "inducement" grants to 31 new employees under Rule
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced precautionary measures the company is taking to help protect the health and safety of its employees, partners, and the healthcare workers and patients involved in ongoing clinical studies of
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in AROHSD1001, a Phase 1/2 clinical study of ARO-HSD, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Barclays Global Healthcare Conference – Miami , March 10-12, 2020 March 11 , 11:15 a.m.
Conference Call and Webcast Today, Feb. 5 at 4:30 p.m. EDT PASADENA, Calif. --(BUSINESS WIRE)--Feb. 5, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2019 . The company is hosting a conference call at 4:30 p.m.
- Multiple-dose data across various patient populations show marked improvement in multiple lipid parameters - Company targets initiation of pivotal studies in 2020 PASADENA, Calif. --(BUSINESS WIRE)--Feb. 5, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today reported promising interim
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 22, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 5, 2020 , at 4:30 p.m. EST to discuss its financial results for the fiscal first quarter ended December 31, 2019 .
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 6, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the appointment of James Hassard to the newly-created position of chief commercial officer. Mr. Hassard will be responsible for driving commercial strategy and building the team and